Prospective registry of antithrombotic Therapy in acute coronary syndromes (ePicor)

pp 6-14

Abstract

Background: We present the two-year follow-up results of the EPICOR study Argentine cohort, a prospective, international, observational, multicenter registry designed to determine the use of antithrombotic therapy patterns in the routine clinical practice of patients with acute coronary syndrome (ACS). The study enrolled a total of 438 consecutive patients with ST-segment elevation myocardial infarction (STEMI, 41%) or non-ST-segment elevation ACS (NSTE-ACS, 59%) discharged alive from public, private, and
community hospitals. Mean age was 62 years, 76% of patients were male, 71% hypertensive, 64% smokers, 19% diabetic and 40% had
history of previous cardiovascular disease. Overall mortality was 4.8% at 1 year and 7.3% at 2 years. Use of dual antiplatelet therapy was 80% at one year and 53% at 2 years (p <0.0001), with no differences between those with or without ST-segment elevation. The 2-year incidence of ischemic and major bleeding events was 15.3% and 1.8%, respectively.
conclusion: Beyond the one-year administration recommended by the guidelines, a high percentage of persistent dual antiplatelet
therapy was observed at 2 years, with a low incidence of major bleeding events, suggesting a clinical risk-benefit selection.